Hiroomi Tada
2023
In 2023, Hiroomi Tada earned a total compensation of $2.4M as Chief Medical Officer at Tyra Biosciences, a 90% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $305,760 |
|---|---|
| Option Awards | $1,596,107 |
| Salary | $509,600 |
| Other | $950 |
| Total | $2,412,417 |
Tada received $1.6M in option awards, accounting for 66% of the total pay in 2023.
Tada also received $305.8K in non-equity incentive plan, $509.6K in salary and $950 in other compensation.
Rankings
In 2023, Hiroomi Tada's compensation ranked 420th out of 2,983 executives tracked by ExecPay. In other words, Tada earned more than 85.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 420 out of 2,983 | 86th |
Division Manufacturing | 239 out of 1,637 | 85th |
Major group Chemicals And Allied Products | 169 out of 906 | 81st |
Industry group Drugs | 166 out of 869 | 81st |
Industry Pharmaceutical Preparations | 104 out of 627 | 83rd |
Source: SEC filing on April 18, 2024.
Tada's colleagues
We found two more compensation records of executives who worked with Hiroomi Tada at Tyra Biosciences in 2023.